Literature DB >> 6276483

Measurement of receptor-independent lipoprotein catabolism using 1,2 cyclohexanedione-modified low density lipoprotein.

H R Slater, C J Packard, J Shepherd.   

Abstract

The utility of 1,2 cyclohexanedione-modified low density lipoprotein (CHD-LDL) as a marker for the measurement of receptor independent LDL catabolism has been assessed by examining its metabolic properties in cultured human fibroblasts and in rabbits. Cell culture studies showed that the inhibition of high affinity membrane receptor binding produced by the modification could be partially reversed by prolonged incubation of the CHD-LDL at 37 degrees C. Pre-exposure of the complex to alkaline pH (pH 10.5) prevented this and yielded a product that was apparently stable. Despite its regained ability to bind to the fibroblast receptor, 125I-labeled CHD-LDL incubated at 37 degrees C for 24 hr either in vivo or in vitro was removed from rabbit plasma in the same manner as freshly prepared 131I-labeled CHD-LDL and as 131I-labeled CHD-LDL that had been treated at pH 10.5. However, its plasma clearance was significantly faster than that of reductively methylated LDL. We believe that this may result from differential catabolism of these modified lipoproteins rather than from susceptibility of the CHD-LDL to receptor-directed catabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6276483

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Quantitative role of parenchymal and non-parenchymal liver cells in the uptake of [14C]sucrose-labelled low-density lipoprotein in vivo.

Authors:  L Harkes; J C Van Berkel
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

2.  Comparison of glucosylated low density lipoprotein with methylated or cyclohexanedione-treated low density lipoprotein in the measurement of receptor-independent low density lipoprotein catabolism.

Authors:  U P Steinbrecher; J L Witztum; Y A Kesaniemi; R L Elam
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

Review 3.  Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect.

Authors:  J Shepherd; C J Packard
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

4.  Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein.

Authors:  Y A Kesaniemi; J L Witztum; U P Steinbrecher
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

5.  Cholesterol feeding increases low density lipoprotein synthesis.

Authors:  C J Packard; L McKinney; K Carr; J Shepherd
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

6.  Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.

Authors:  M Samadi-Baboli; G Favre; P Canal; G Soula
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.